Windtree Therapeutics Inc WINT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if WINT is a good fit for your portfolio.
News
-
Windtree Therapeutics Announces Reverse Stock Split
-
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
-
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
-
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
-
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
Trading Information
- Previous Close Price
- $5.07
- Day Range
- $5.04–5.51
- 52-Week Range
- $4.78–35.10
- Bid/Ask
- $5.06 / $5.36
- Market Cap
- $2.67 Mil
- Volume/Avg
- 28,473 / 14,708
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.windtreetx.com
Valuation
|
Metric
|
WINT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.50 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
WINT
Financial Strength
|
Metric
|
WINT
|
|---|---|
Quick Ratio | 1.08 |
Current Ratio | 1.35 |
Interest Coverage | −411.32 |
Quick Ratio
WINT
Profitability
|
Metric
|
WINT
|
|---|---|
Return on Assets (Normalized) | −43.77% |
Return on Equity (Normalized) | −201.75% |
Return on Invested Capital (Normalized) | −161.62% |
Return on Assets
WINT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tmdqjwznt | Bcjhs | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hqwccqxld | Bzbxcl | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Chcpdmw | Hlklpw | $97.8 Bil | |
MRNA
| Moderna Inc | Zgzssywt | Lwxl | $38.8 Bil | |
ARGX
| argenx SE ADR | Qdfpfcfp | Jrlk | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Qyrbvrpkm | Ysd | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hdxckpgzz | Rvvhgtb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ckxvnvffy | Ysbdxy | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wrfdwxrtp | Zdrtqvs | $12.5 Bil | |
INCY
| Incyte Corp | Bljskfjv | Hmgcpwj | $11.5 Bil |